| MeSH term | MeSH ID | Detail |
|---|---|---|
| Hypercholesterolemia | D006937 | 91 associated lipids |
| Bradycardia | D001919 | 13 associated lipids |
| Endometriosis | D004715 | 29 associated lipids |
| Myocardial Infarction | D009203 | 21 associated lipids |
| Proteinuria | D011507 | 30 associated lipids |
| Drug Hypersensitivity | D004342 | 20 associated lipids |
| Arteriosclerosis | D001161 | 86 associated lipids |
| Carcinoma, Hepatocellular | D006528 | 140 associated lipids |
| Fractures, Open | D005597 | 3 associated lipids |
| Arthritis, Infectious | D001170 | 8 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (5)
- Drug Metab. Dispos. (1)
- FEMS Immunol. Med. Microbiol. (1)
- Others (5)
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Muller MG et al. | Acinetobacter baumannii in Localised Cutaneous Mycobacteriosis in Falcons. | 2010 | Vet Med Int | pmid:20871867 |
| Weese JS et al. | Antimicrobial use guidelines for treatment of urinary tract disease in dogs and cats: antimicrobial guidelines working group of the international society for companion animal infectious diseases. | 2011 | Vet Med Int | pmid:21776346 |
| Dhama K et al. | Tuberculosis in Birds: Insights into the Mycobacterium avium Infections. | 2011 | Vet Med Int | pmid:21776352 |
| Giguère S | Treatment of Infections Caused by Rhodococcus equi. | 2017 | Vet. Clin. North Am. Equine Pract. | pmid:28161038 |
| Sharman MJ et al. | Gastrokine mRNA expression in gastric tissue from dogs with helicobacter colonisation but without inflammatory change during treatment. | 2017 | Vet. Immunol. Immunopathol. | pmid:28494926 |
| Hung SW et al. | Antibiotic susceptibility and prevalence of erythromycin ribosomal methylase gene, erm(B) in Streptococcus spp. | 2008 | Vet. J. | pmid:17400007 |
| Berghaus LJ et al. | Mutant prevention concentration and mutant selection window for 10 antimicrobial agents against Rhodococcus equi. | 2013 | Vet. Microbiol. | pmid:23915992 |
| Hartmann FA et al. | Molecular characterization of Staphylococcus intermedius carriage by healthy dogs and comparison of antimicrobial susceptibility patterns to isolates from dogs with pyoderma. | 2005 | Vet. Microbiol. | pmid:15917140 |
| Burton AJ et al. | Efficacy of liposomal gentamicin against Rhodococcus equi in a mouse infection model and colocalization with R. equi in equine alveolar macrophages. | 2015 | Vet. Microbiol. | pmid:25666452 |
| Giguère S et al. | In vitro synergy, pharmacodynamics, and postantibiotic effect of 11 antimicrobial agents against Rhodococcus equi. | 2012 | Vet. Microbiol. | pmid:22704561 |
| Sieber-Ruckstuhl NS et al. | Long-term cure of disseminated Mycobacterium avium infection in a cat. | 2007 | Vet. Rec. | pmid:17259458 |
| Cattoli G et al. | Helicobacter acinonychis eradication leading to the resolution of gastric lesions in tigers. | 2000 | Vet. Rec. | pmid:10975334 |
| Bruhn O et al. | Antimicrobial peptides and proteins of the horse--insights into a well-armed organism. | 2011 | Vet. Res. | pmid:21888650 |
| Clark SE et al. | Identification of a multidrug efflux pump in Flavobacterium johnsoniae. | Vet. Res. | pmid:19558960 | |
| Ebnöther M et al. | Severe bronchiolitis in acute Mycoplasma pneumoniae infection. | 2001 | Virchows Arch. | pmid:11787856 |
| de Mascarel A et al. | Clinical, histological and molecular follow-up of 60 patients with gastric marginal zone lymphoma of mucosa-associated lymphoid tissue. | 2005 | Virchows Arch. | pmid:15742170 |
| Zarogoulidis P et al. | Long-term respiratory follow-up of H1N1 infection. | 2011 | Virol. J. | pmid:21702977 |
| Morgene MF et al. | HaCaT epithelial cells as an innovative novel model of rhinovirus infection and impact of clarithromycin treatment on infection kinetics. | 2018 | Virology | pmid:30077071 |
| Sandri A et al. | Inhibition of Pseudomonas aeruginosa secreted virulence factors reduces lung inflammation in CF mice. | 2018 | Virulence | pmid:29938577 |
| DÃte P et al. | [Double blind randomized multicentre study of a seven-day eradication regime of Helicobacter pylori by omeprazole, clarithromycin and ornidazole vs. omeprazole, clarithromycin and metronidazole]. | 2002 | Vnitr Lek | pmid:16737149 |
| Starostin BD | [Modern means of anti-Helicobacter therapy]. | 2001 | Voen Med Zh | pmid:11764485 |
| Vichev E et al. | [Gastroduodenitis and ulcers--statistical study for 1998]. | 2000 | Vutr Boles | pmid:11688321 |
| Yazdanbakhsh AR et al. | Reduction of non-Betalactam Antibiotics COD by Combined Coagulation and Advanced Oxidation Processes. | 2016 | Water Environ. Res. | pmid:28661328 |
| Nakada N et al. | Removal of selected pharmaceuticals and personal care products (PPCPs) and endocrine-disrupting chemicals (EDCs) during sand filtration and ozonation at a municipal sewage treatment plant. | 2007 | Water Res. | pmid:17632207 |
| Abegglen C et al. | The fate of selected micropollutants in a single-house MBR. | 2009 | Water Res. | pmid:19269669 |
| Vione D et al. | Phototransformation of selected human-used macrolides in surface water: kinetics, model predictions and degradation pathways. | 2009 | Water Res. | pmid:19249811 |
| Wang S et al. | Enhanced adsorption of ionizable antibiotics on activated carbon fiber under electrochemical assistance in continuous-flow modes. | 2018 | Water Res. | pmid:29426033 |
| Siemens J et al. | Concentrations and mobility of human pharmaceuticals in the world's largest wastewater irrigation system, Mexico City-Mezquital Valley. | 2008 | Water Res. | pmid:18083208 |
| Forrez I et al. | Biogenic metals for the oxidative and reductive removal of pharmaceuticals, biocides and iodinated contrast media in a polishing membrane bioreactor. | 2011 | Water Res. | pmid:21163512 |
| Yamashita N et al. | Effects of antibacterial agents, levofloxacin and clarithromycin, on aquatic organisms. | 2006 | Water Sci. Technol. | pmid:16862775 |
| Sahar E et al. | Comparison of two treatments for the removal of selected organic micropollutants and bulk organic matter: conventional activated sludge followed by ultrafiltration versus membrane bioreactor. | 2011 | Water Sci. Technol. | pmid:21330721 |
| Lin AY et al. | Fate of selected pharmaceuticals and personal care products after secondary wastewater treatment processes in Taiwan. | 2010 | Water Sci. Technol. | pmid:21076233 |
| Ghosh GC et al. | Occurrence and elimination of antibiotics at four sewage treatment plants in Japan and their effects on bacterial ammonia oxidation. | 2009 | Water Sci. Technol. | pmid:19237773 |
| Harada A et al. | Biological effects of PPCPs on aquatic lives and evaluation of river waters affected by different wastewater treatment levels. | 2008 | Water Sci. Technol. | pmid:19001705 |
| Nakada N et al. | Occurrence of 70 pharmaceutical and personal care products in Tone River basin in Japan. | 2007 | Water Sci. Technol. | pmid:18075189 |
| Sein MM et al. | Oxidation of some typical wastewater contaminants (tributyltin, clarithromycin, metoprolol and diclofenac) by ozone. | 2009 | Water Sci. Technol. | pmid:19403960 |
| Feng X et al. | [Interaction between biofilm formed by Pseudomonas aeruginosa and antibacterial agents]. | 2000 | Wei Sheng Wu Xue Bao | pmid:12548947 |
| Dhawan VK et al. | Vancomycin-resistant enterococcal colonization in nonhospitalized HIV-infected patients. | 1998 | West. J. Med. | pmid:9830355 |
| Kanatani MS and Guglielmo BJ | The new macrolides. Azithromycin and clarithromycin. | 1994 | West. J. Med. | pmid:8128699 |
| Kardas P and Muras M | [A blinded comparison of palatability of 13 common pediatric antibiotic suspensions]. | 2005 | Wiad. Lek. | pmid:15991547 |
| Gościmski A et al. | [Microflora of gastric juice in patients after eradication of Helicobacter pylori and treatment with a proton pump inhibitor]. | 2002 | Wiad. Lek. | pmid:12043311 |
| Kurz H and Göpfrich H | [Epidemiology and morbidity of mycoplasma as causative agent for community-acquired pneumonia in hospitalized children in a Community Hospital in Vienna]. | 2011 | Wien Med Wochenschr | pmid:20963506 |
| Bago P et al. | High eradication rate of H. pylori with moxifloxacin-based treatment: a randomized controlled trial. | 2007 | Wien. Klin. Wochenschr. | pmid:17634896 |
| Bago J et al. | The impact of primary antibiotic resistance on the efficacy of ranitidine bismuth citrate- vs. omeprazole-based one-week triple therapies in H. pylori eradication--a randomised controlled trial. | 2002 | Wien. Klin. Wochenschr. | pmid:12422579 |
| Bago J et al. | Comparison of the efficacy of 250 mg and 500 mg clarithromycin used with lansoprazole and amoxicillin in eradication regimens for Helicobacter pylori infection. | 2004 | Wien. Klin. Wochenschr. | pmid:15379146 |
| Vcev A et al. | Amoxycillin, clarithromycin and either sucralfate or pantoprazole for eradication of Helicobacter pylori in duodenal ulcer (a randomized controlled trial). | 2001 | Wien. Klin. Wochenschr. | pmid:11802510 |
| Li Y et al. | Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis. | 2010 | Wien. Klin. Wochenschr. | pmid:20628905 |
| NiziÄ T et al. | Solitary erythema migrans in children: comparison of treatment with clarithromycin and amoxicillin. | 2012 | Wien. Klin. Wochenschr. | pmid:22760494 |
| Francesco VD et al. | Mechanisms of Helicobacter pylori antibiotic resistance: An updated appraisal. | 2011 | World J Gastrointest Pathophysiol | pmid:21860834 |
| Yanai A et al. | Non-bismuth quadruple therapy for first-line Helicobacter pylori eradication: A randomized study in Japan. | 2012 | World J Gastrointest Pharmacol Ther | pmid:22408744 |